CN113683691A - 黄病毒抗体及其应用 - Google Patents

黄病毒抗体及其应用 Download PDF

Info

Publication number
CN113683691A
CN113683691A CN202110955389.5A CN202110955389A CN113683691A CN 113683691 A CN113683691 A CN 113683691A CN 202110955389 A CN202110955389 A CN 202110955389A CN 113683691 A CN113683691 A CN 113683691A
Authority
CN
China
Prior art keywords
ser
gly
thr
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110955389.5A
Other languages
English (en)
Other versions
CN113683691B (zh
Inventor
高福
严景华
李燕
仵丽丽
王奇慧
马素芳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Microbiology of CAS
Original Assignee
Institute of Microbiology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Microbiology of CAS filed Critical Institute of Microbiology of CAS
Priority to CN202110955389.5A priority Critical patent/CN113683691B/zh
Publication of CN113683691A publication Critical patent/CN113683691A/zh
Application granted granted Critical
Publication of CN113683691B publication Critical patent/CN113683691B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

黄病毒抗体及其应用。本发明公开了黄病毒抗体，包括重链可变区和轻链可变区，其中所述重链可变区及轻链可变区的氨基酸序列如序列表中所示。还公开了编码所述重链可变区和轻链可变区的核苷酸酸序列以及本发明抗体在制备用于检测、治疗和/或预防黄病毒药物或试剂上的应用、及包含本发明抗体的药物组合物或试剂。该抗体对于黄病毒具有高亲和力。

Description

黄病毒抗体及其应用
技术领域
本发明涉及生物医药技术领域，具体涉及黄病毒抗体及其应用。
背景技术
黄病毒基于传播载体分为三大类：蚊媒黄病毒、蜱媒黄病毒和无已知传播载体的黄病毒。黄热病毒、寨卡病毒、西尼罗病毒、日本脑炎病毒和登革热病毒均属于蚊媒黄病毒，而蜱传脑炎病毒和跳跃病病毒均属于蜱媒黄病毒。黄热病毒感染主要引起发热、肌肉疼痛、头痛、寒战、食欲不振、恶心和呕吐，严重的产生高热、黄启腹痛并伴有呕吐，甚至死亡；登革热感染则引起高热、头疼、肌肉骨关节疼痛等临床表现，是东南亚地区儿童死亡的主要原因之一：西尼罗病毒感染严重时将引起无菌性脑膜炎，甚至死亡。
目前诊断黄病毒感染的实验室方法主要包括病毒分离、核酸检测、抗原检测和血清学检测等。目前最可靠的诊断方法主要是提取病毒RNA后进行qRT-PCR，该方法费时、成本高昂且需要在特定的实验室由专业人员进行操作，使用的仪器也较复杂，无法广泛便捷的应用。因此，迫切需要开发一种操作简单、可在感染早期即可检测产品和方法，且可在偏远地区使用。
最近已经报道了黄病毒的非结构蛋白1(nonstructural protein 1，NS1)是比较保守的糖蛋白，有膜型和分泌型两种形式，在感染机体中表达量高且时间长，是检测病毒感染的良好靶点。
发明内容
为解决上述技术问题，本发明的目的在于提供一种黄病毒抗体，能与黄病毒NS1蛋白结合，具有较高的亲和力以及较好的稳定性。
一种黄病毒抗体，所述抗体包含如下(1)-(4)中任一氨基酸序列：
(1)如氨基酸序列SEQ ID NO：1所示的抗体重链可变区，如氨基酸序列SEQ ID NO：2所示的抗体轻链可变区；
(2)如氨基酸序列SEQ ID NO：3所示的抗体重链可变区，如氨基酸序列SEQ ID NO：4所示的抗体轻链可变区；
(3)如氨基酸序列SEQ ID NO：5所示的抗体重链可变区，如氨基酸序列SEQ ID NO：6所示的抗体轻链可变区；
(4)如氨基酸序列SEQ ID NO：7所示的抗体重链可变区，如氨基酸序列SEQ ID NO：8所示的抗体轻链可变区。
以上所述的抗体，其中，包括所述氨基酸序列SEQ ID NO：9所示的抗体重链恒定区，如氨基酸序列SEQ ID NO：10所示的抗体轻链恒定区。
以上所述的抗体，其中，所述抗体重链恒定区的编码核苷酸序列如SEQ ID NO：11所示，所述抗体轻链恒定区的编码核苷酸序列如SEQ ID NO：12所示。
以上所述的抗体，其中，所述抗体还包括信号肽序列，所述信号肽的氨基酸序列如SEQ ID NO：13所示，所述信号肽序列的编码核苷酸序列如SEQ ID NO：14所示。
以上所述的抗体，其中，所述氨基酸轻链均为K型轻链。
本发明的一种核酸分子，其中，所述核酸分子包含编码以上所述抗体的核苷酸序列，所述核苷酸序列如下：
(1)如核苷酸序列SEQ ID NO：15所示的氨基酸重链可变区，如核苷酸序列SEQ IDNO：16所示的氨基酸轻链可变区；
(2)如核苷酸序列SEQ ID NO：17所示的氨基酸重链可变区，如核苷酸序列SEQ IDNO：18所示的氨基酸轻链可变区；
(3)如核苷酸序列SEQ ID NO：19所示的氨基酸重链可变区，如核苷酸序列SEQ IDNO：20所示的氨基酸轻链可变区；
(4)如核苷酸序列SEQ ID NO：21所示的氨基酸重链可变区，如核苷酸序列SEQ IDNO：22所示的氨基酸轻链可变区。
本发明还包含以上所述核酸分子的表达载体。
本发明还包含以上所述表达载体的宿主细胞。
本发明的一种药物组合物，其中，包含以上任一所述的抗体。
本发明的一种检测试剂，其中，包含以上权利要求中任一所述的抗体。
本发明的一种检测试剂盒，其中，包含以上权利要求中任一所述的抗体。
以上任一所述抗体在制备检测、治疗和/或预防黄病毒药物或试剂上的应用。
以上所述的应用，其中，所述黄病毒包括黄热病毒、寨卡病毒、西尼罗病毒以及登革热病毒四种血清型。
有益效果
本发明提供的黄病毒抗体与黄病毒具有高亲和力，对于黄病毒的检测以及检测产品的制备都具有较高的应用价值，提供了一种检测黄病毒的新方法，能够快速、准确的完成检测。
附图说明
图1为黄热病毒YFV-NS1蛋白的亲和层析及SDS-PAGE鉴定结果图；
图2为寨卡病毒ZIKV-NS1蛋白的亲和层析及SDS-PAGE鉴定结果图；
图3为血清型登革热病毒DV1-NS1/DV2-NS1/DV3-NS1/DV4-NS1蛋白的亲和层析及SDS-PAGE鉴定结果图；
图4为西尼罗病毒WN-NS1蛋白的亲和层析及SDS-PAGE鉴定结果图；
图5为抗体蛋白通过Western Blotting和SDS-PAGE鉴定的结果图；
图6为测定黄病毒抗体的结合活性的结果图；
图7为测定黄病毒抗体亲和力的结果图。
具体实施方式
以下实施例用于说明本发明，但不用来限制本发明的范围。若未特别指明，实施例中所用的技术手段为本领域技术人员所熟知的常规手段。
实施例1人源抗体的制备
一、黄热病毒非结构蛋白1(YFV-NS1)的表达与纯化
YFV-NS1的胞外区基因片段通过Nde I和Xho I克隆至pFastBac I载体中，转化至大肠杆菌DH10，获得重组质粒Bacmid-NS1。然后，转染sf9细胞，获得含有NS1基因的杆状病毒。杆状病毒感染Hi5细胞后，可分泌表达NS1蛋白至培养上清。通过亲和层析和分子筛层析的方法进行纯化，通过SDS-PAGE鉴定蛋白纯度。结果显示，NS1蛋白存在单体和二聚体形式，单体大小为43kDa(如SEQ ID NO：23所示)，结果如图1。将YFV-NS1浓缩至1mg/mL，冷冻保存于-80℃备用。
其他黄病毒属病毒WNV-NS1、ZIKV-NS1、DENV-NS1(DV1-NS1/DV2-NS1/DV3-NS1/DV4-NS1构建、表达和纯化参考上述YFV-NS1。
二、其他黄病毒NS1蛋白的表达与纯化
其他黄病毒属病毒：寨卡病毒ZIKV-NS1(大小约为45kDa，如SEQ ID NO：24所示，如图2所示)，四种血清型登革热病毒DENV-NS1(DV1-NS1/DV2-NS1/DV3-NS1/DV4-NS1蛋白，大小分别为45kDa/75kDa/43kDa/43kDa，如图3所示，如SEQ ID NO：25-28所示，)，西尼罗病毒WNV-NS1(大小为45kDa，如SEQ ID NO：29所示，如图4所示)、蛋白表达纯化过程参考上述YFV-NS1蛋白表达纯化方法。
三、人源单克隆抗体的制备
1单细胞分选和克隆构建
取得康复者知情同意的情况下，采集两名感染YFV6个月的康复者的外周血样本，分离外周血单核细胞(PBMCs)，加入各类血细胞特异性标记抗体和特异性YFV-NS1抗原一起孵育。经FACSAria II(BD Biosciences)分选，收集YFV-NS1阳性的的记忆型B细胞至96孔板中，每孔1个细胞。
通过RT-PCR和巢式PCR的方法从单个B细胞中扩增抗体可变区基因序列(VH和VL)。首先，将获得的B细胞通过SuperScript III reverse transcriptase试剂盒进行逆转录。获得cDNA后，采用HotStar plus酶(QIAGEN)进行巢式PCR来扩增抗体可变区序列。第一轮PCR反应条件如下：95℃5min；95℃ 30s，55℃(VH和Vκ)或50℃(Vλ)60s，72℃90s，35个循环；72℃7min。将获得的产物作为模板进行第二轮PCR，条件如下：95℃5min；95℃30s，58℃(重链)/60℃(K链)/64℃(λ链)30s，72℃90s，35个循环；72℃7min。
采用琼脂糖凝胶电泳，分离PCR产物，用凝胶提取试剂盒(CWBIO)提取分子量约为400bp的PCR条带，并将纯化后的产物进行测序。利用IMGT(internationalImMunoGeneTics)信息***和IgBlast对获得的靶序列进行分析。可变区序列与相对应的应的恒定区通过搭桥PCR连接，克隆至表达载体pCAGGS中，其中重链与λ链采用EcoRI和XhoI酶切位点，κ链采用SacI与XhoI酶切位点。
2蛋白表达和纯化
将重链和轻链构建质粒转染HEK-293T细胞。转染6小时后用更换为新鲜的无血清的培养基进行培养。第3天和第7天，收集细胞培养上清。将收集的上清与含有20mM磷酸钠(pH 7.0)的缓冲液等体积混合，6500rpm离心30min去掉碎片，经过0.22um的滤膜过滤后，上清液流过HiTrap Protein A亲和层析柱，然后使用0.1M甘氨酸(pH 3.0)洗脱结合的抗体。收集洗脱液浓缩后进行分子筛层析。目的峰通过SDS-PAGE，结果如图5，分离出11种抗体，重链约为45kDa，轻链约为25kDa，说明目标蛋白得到正常表达。
实施例2抗体的功能鉴定
一、ELISA检测抗体的结合活性
1)使用包被液稀释抗原2μg/mL(YFV-NS1、YFV-NS1 C terminal、WNV-NS1、ZIKV-NS1、DENV1-NS1、DENV2-NS1、DENV3-NS1、DENV4-NS1)，加至酶标板中，100μL/孔，4℃过夜。
2)第二天，加入PBST 200μL/孔，洗板机(BIO-TEK，405LS)洗板5次后，加入5％的脱脂奶粉封闭液，100μL/孔，37℃孵箱孵育1小时。
3)PBST漂洗5次，加入抗体YB31、YB44、YD4或YD33，400ng/孔，37℃孵箱孵育1小时。
4)PBST漂洗5次，将HPR标记的羊抗人IgG，100μL/孔，37℃孵箱孵育45min。
5)PBST漂洗5次，加入TMB显色液，100μL/孔，室温避光，反应2分钟，之后加入2MH2SO4终止反应，100μL/孔。
6)检测450nm波长处的OD值，保存记录原始数据。
结果：见图6，结果表明本发明的黄病毒抗体YB31、YB44、YD4或YD33与YFV-NS1/DV1-NS1/DV2-NS1/DV3-NS1/DV4-NS1/WN-NS1蛋白均可以结合，结合活性较高。不结合ZIKV-NS1蛋白。
二、抗体YB31、YB44、YD4、YD33与抗YFV-NS1的结合亲和力测定
此项实验采用BIAcoreTM 8K机器完成。具体步骤如下：
首先，将抗人的二抗以氨基偶联的方式固定在CM5芯片的通道(flow cell，Fc)。固定量控制在10,000响应值(response units，RU)左右。以抗体捕获的方式固定YB31、YB44、YD4或YD33，捕获量在60RU左右。缓冲液(10mM HEPES，150mMNaCl，pH 7.4)倍比稀释YFV-NS1蛋白，依次流过各通道，流速为30μL/min。利用BIAeva1uation software (Biacore，Inc.)软件计算结合动力学常数。
SPR的结果显示，抗体均可以与YFV-NS1蛋白结合(图7)。得到的各相互作用的结合常数(ka)、解离常数(kd)和平衡解离常数(kD)，如表1所示。
表1
Figure BDA0003220032840000031
虽然，上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述，但在本发明基础上，可以对之作一些修改或改进，这对本领域技术人员而言是显而易见的。因此，在不偏离本发明精神的基础上所做的这些修改或改进，均属于本发明要求保护的范围。
序列表
<110> 中国科学院微生物研究所
<120> 黄病毒抗体及其应用
<130> P210071
<160> 29
<170> SIPOSequenceListing 1.0
<210> 1
<211> 122
<212> PRT
<213> 人工序列(Synthetic sequences)
<400> 1
Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Asn Tyr
20 25 30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Tyr Pro Asp Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65 70 75 80
Leu Gln Trp Arg Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Arg Met Gly Gly Asp Arg Ala Pro Asn Trp Phe Asp Ile Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 2
<211> 107
<212> PRT
<213> 人工序列(Synthetic sequences)
<400> 2
Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Thr Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Glu Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Ile Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Phe Gly Thr Leu Val
85 90 95
Ala Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 3
<211> 120
<212> PRT
<213> 人工序列(Synthetic sequences)
<400> 3
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Cys Val
35 40 45
Ser His Ile Thr Gly Asn Gly Val Thr His Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Glu Val Ala Tyr Ser Asp Tyr Asp Tyr Ser Asp Val Trp Gly Gln
100 105 110
Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 4
<211> 108
<212> PRT
<213> 人工序列(Synthetic sequences)
<400> 4
Asp Ile Gln Leu Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ala Trp
20 25 30
Leu Ala Trp Tyr Gln Tyr Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Glu Ala Ser Asn Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Cys Tyr Thr Tyr Ser Gln
85 90 95
Trp Ala Phe Gly Gln Gly Thr Lys Val Asp Ile Lys
100 105
<210> 5
<211> 125
<212> PRT
<213> 人工序列(Synthetic sequences)
<400> 5
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Asp Ser His
20 25 30
Ala Val His Trp Val Arg Gln Ala Pro Gly Gln Arg Pro Glu Trp Met
35 40 45
Gly Trp Val Asn Val Ala Asn Gly Gln Arg Lys Tyr Ser Glu Asn Leu
50 55 60
Arg Gly Arg Leu Thr Ile Ile Arg Asp Ile Ser Ala Thr Thr Ala Tyr
65 70 75 80
Met Glu Leu Thr Ser Leu Arg Pro Glu Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ala Arg Asp Asn Leu Asp Gly Asp Tyr Asn Ala Tyr Tyr Tyr Gly Met
100 105 110
Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 6
<211> 107
<212> PRT
<213> 人工序列(Synthetic sequences)
<400> 6
Glu Ile Val Leu Thr Gln Ser Pro Ser Leu Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Tyr Ser
20 25 30
Leu Ala Trp Tyr Arg Gln Lys Pro Gly Lys Ala Pro Asp Leu Leu Val
35 40 45
Tyr Asp Ser Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Lys Thr Phe Pro His
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Asp Val Lys
100 105
<210> 7
<211> 121
<212> PRT
<213> 人工序列(Synthetic sequences)
<400> 7
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Thr Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Ser Gly Asn Gly Val Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Gln Gly Arg Phe Thr Ile Ser Arg Asp Lys Ser Lys Lys Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Asp Val His Trp Asn Asp Ala Gly Tyr Cys Asp Ser Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 8
<211> 107
<212> PRT
<213> 人工序列(Synthetic sequences)
<400> 8
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Phe Ser Thr Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Glu Ala Ser Arg Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Glu Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
<210> 9
<211> 330
<212> PRT
<213> 人工序列(Synthetic sequences)
<400> 9
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
225 230 235 240
Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330
<210> 10
<211> 108
<212> PRT
<213> 人工序列(Synthetic sequences)
<400> 10
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
1 5 10 15
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
20 25 30
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
35 40 45
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
50 55 60
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
65 70 75 80
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
85 90 95
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Ser
100 105
<210> 11
<211> 993
<212> DNA
<213> 人工序列(Synthetic sequences)
<400> 11
gccagcacca aaggcccgag cgtgtttccg ctggcgccga gcagcaaaag caccagcggc 60
ggcaccgcgg cgctgggctg cctggtgaaa gattattttc cggaaccggt gaccgtgagc 120
tggaacagcg gcgcgctgac cagcggcgtg catacctttc cggcggtgct gcagagcagc 180
ggcctgtata gcctgagcag cgtggtgacc gtgccgagca gcagcctggg cacccagacc 240
tatatttgca acgtgaacca taaaccgagc aacaccaaag tggataaacg cgtggagccc 300
aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctgaact cctgggggga 360
ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct 420
gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 480
tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac 540
agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag 600
gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc 660
aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggatgag 720
ctgaccaaga accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc 780
gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg 840
ctggactccg acggctcctt cttcctctac agcaagctca ccgtggacaa gagcaggtgg 900
cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg 960
cagaagagcc tctccctgtc tccgggtaaa tga 993
<210> 12
<211> 327
<212> DNA
<213> 人工序列(Synthetic sequences)
<400> 12
cgaactgtgg ctgcaccatc tgtgttcatc ttccctccca gcgacgagca gctgaagagc 60
ggcaccgcca gcgtggtctg tctcctgaac aacttctatc ccagggaggc caaggtccag 120
tggaaagtgg acaacgccct gcaaagcggc aatagccagg agtccgtcac agagcaggac 180
agcaaggaca gcacctacag cctgtccagc accctgaccc tcagcaaggc cgactacgag 240
aagcacaagg tgtacgcttg cgaggtgacc catcagggcc tgtccagccc cgtgaccaag 300
tccttcaaca ggggcgaatg cagctaa 327
<210> 13
<211> 21
<212> PRT
<213> 人工序列(Synthetic sequences)
<400> 13
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15
Gly Ser Thr Gly Asp
20
<210> 14
<211> 63
<212> DNA
<213> 人工序列(Synthetic sequences)
<400> 14
atggagacgg atacgctgct cctgtgggtt ttgctgctgt gggttccagg ttccactggt 60
gac 63
<210> 15
<211> 366
<212> DNA
<213> 人工序列(Synthetic sequences)
<400> 15
gaggttcagc tggtggagtc tggggcagag gtgaaaaagc ccggggagtc tctgaagatc 60
tcctgtaagg gttctggata cagctttagc aactactgga tcggctgggt gcgccagatg 120
cccgggaaag gcctggagtg gatgggaatc atctatcctg atgactctga taccagatat 180
agcccgtcct tccaaggcca ggtcaccatc tcagccgaca agtccatcag caccgcctac 240
ctgcagtgga ggagcctgaa ggcctcggac accgccatgt attactgtgc gagacgcatg 300
ggcggggata gagcaccaaa ctggttcgat atatggggcc agggaaccct ggtcaccgtc 360
tcctca 366
<210> 16
<211> 321
<212> DNA
<213> 人工序列(Synthetic sequences)
<400> 16
gaaattgtgt tgacgcagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcaagtca gagcattggc acctatttaa attggtatca acagaaacca 120
ggggaagccc ctaagctcct gatctatgct gcatccattt tgcaaagtgg ggtcccatca 180
aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240
gaagattttg caacttacta ctgtcaacag agtttcggta ccctggtcgc ttttggccag 300
gggaccaaac tggagatcaa a 321
<210> 17
<211> 360
<212> DNA
<213> 人工序列(Synthetic sequences)
<400> 17
gaggttcagc tggtggagtc tgggggaggc ttggtacagg cgggggggtc cctgagactc 60
tcctgtgcag cctctggatt cacctttagc agctatgcca tgaactgggt ccgccaggct 120
ccagggaagg ggctggagtg cgtctcacat attactggta atggagttac acattacgca 180
gactccgtga agggccgatt caccatctcc agagacaatt ccaagaacac actgtatctg 240
caaatgaaca gcctgagagt cgaggacacg gccgtatatt actgtgcgaa agaagtggca 300
tatagtgact acgattactc ggacgtctgg ggccaaggga cgacggtcac cgtctcctca 360
<210> 18
<211> 324
<212> DNA
<213> 人工序列(Synthetic sequences)
<400> 18
gacatccagt tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt gcctggttgg cctggtatca gtataaacca 120
gggaaagccc cgaagctcct gatctatgag gcttctaatt tagaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 240
gatgattttg caacttatta ctgccaacag tgttacactt attctcagtg ggcgttcggc 300
caagggacca aggtggacat caaa 324
<210> 19
<211> 375
<212> DNA
<213> 人工序列(Synthetic sequences)
<400> 19
caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttccggata catcttcgat agccacgctg tgcattgggt gcgccaggcc 120
cccggtcaaa ggccagagtg gatgggatgg gtcaacgttg ccaatggtca gaggaagtat 180
tcagagaact tgcggggcag actcaccata attagggaca tatccgcgac cacagcctac 240
atggagctga ccagcctgag acctgaagat acggctatat attactgtgc gagagataac 300
ttagacggtg actacaacgc ctactactac ggcatggacg tctggggcca ggggaccacg 360
gtcaccgtct cctca 375
<210> 20
<211> 321
<212> DNA
<213> 人工序列(Synthetic sequences)
<400> 20
gaaattgtgt tgacgcagtc tccatccctc ctgtctgcat ctgtcggaga cagagtcacc 60
atcacttgcc gggccagtca gggcattagc tattctttag cctggtatcg gcaaaaacca 120
gggaaagccc ctgatctcct ggtctatgat tcatccactt tgcaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct 240
gaagattttg caacttatta ctgtcaacaa cttaaaactt tccctcacac ttttggccag 300
gggaccaagc tggacgtcaa a 321
<210> 21
<211> 363
<212> DNA
<213> 人工序列(Synthetic sequences)
<400> 21
gaggttcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc actcagactc 60
tcctgtgtag cctctggatt cacctttagc agttatgcca tgacctgggt ccgccaggct 120
ccagggaggg ggctggagtg ggtctcatca attagtggaa atggtgttag cacatattac 180
gcagactccg tgcagggccg cttcaccatc tccagagaca aatccaagaa gacgctgtat 240
ctgcaaatga acagcctgag agccgaggac acggccgttt attactgtgc gaaggatgta 300
cactggaacg acgctggata ctgtgactcc tggggccagg gaactcttgt gaccgtctcc 360
tca 363
<210> 22
<211> 321
<212> DNA
<213> 人工序列(Synthetic sequences)
<400> 22
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagctttagt acctggttgg cctggtatca gcagaaacca 120
gggaaagcac ctaaggtcct gatctatgag gcgtctagat tagaaagtgg ggtcccatcg 180
aggttcagcg gcagtgaatc tgggacagaa ttcactctca ccatcagtag cttgcagcct 240
gatgattttg caacttatta ctgccaacaa tataatagtt atccactcac tttcggcgga 300
gggaccaagg tggagatcaa a 321
<210> 23
<211> 351
<212> PRT
<213> 人工序列(Synthetic sequences)
<400> 23
Val Gly Cys Ser Val Asp Phe Ser Lys Lys Glu Thr Arg Cys Gly Thr
1 5 10 15
Gly Val Phe Val Tyr Asn Asp Val Glu Ala Trp Arg Asp Arg Tyr Lys
20 25 30
Tyr His Pro Asp Ser Pro Arg Arg Leu Ala Ala Ala Val Lys Gln Ala
35 40 45
Trp Glu Asp Gly Ile Cys Gly Ile Ser Ser Val Ser Arg Met Glu Asn
50 55 60
Ile Met Trp Arg Ser Val Glu Gly Glu Leu Asn Ala Ile Leu Glu Glu
65 70 75 80
Asn Gly Val Gln Leu Thr Val Val Val Gly Ser Val Lys Asn Pro Met
85 90 95
Trp Arg Gly Pro Gln Arg Leu Pro Val Pro Val Asn Glu Leu Pro His
100 105 110
Gly Trp Lys Ala Trp Gly Lys Ser Tyr Phe Val Arg Ala Ala Lys Thr
115 120 125
Asn Asn Ser Phe Val Val Asp Gly Asp Thr Leu Lys Glu Cys Pro Leu
130 135 140
Lys His Arg Ala Trp Asn Ser Phe Leu Val Glu Asp His Gly Phe Gly
145 150 155 160
Val Phe His Thr Ser Val Trp Leu Lys Val Arg Glu Asp Tyr Ser Leu
165 170 175
Glu Cys Asp Pro Ala Val Ile Gly Thr Ala Val Lys Gly Lys Glu Ala
180 185 190
Val His Ser Asp Leu Gly Tyr Trp Ile Glu Ser Glu Lys Asn Asp Thr
195 200 205
Trp Arg Leu Lys Arg Ala His Leu Ile Glu Met Lys Thr Cys Glu Trp
210 215 220
Pro Lys Ser His Thr Leu Trp Thr Asp Gly Ile Glu Glu Ser Asp Leu
225 230 235 240
Ile Ile Pro Lys Ser Leu Ala Gly Pro Leu Ser His His Asn Thr Arg
245 250 255
Glu Gly Tyr Arg Thr Gln Met Lys Gly Pro Trp His Ser Glu Glu Leu
260 265 270
Glu Ile Arg Phe Glu Glu Cys Pro Gly Thr Lys Val His Val Glu Glu
275 280 285
Thr Cys Gly Thr Arg Gly Pro Ser Leu Arg Ser Thr Thr Ala Ser Gly
290 295 300
Arg Val Ile Glu Glu Trp Cys Cys Arg Glu Cys Thr Met Pro Pro Leu
305 310 315 320
Ser Phe Arg Ala Lys Asp Gly Cys Trp Tyr Gly Met Glu Ile Arg Pro
325 330 335
Arg Lys Glu Pro Glu Ser Asn Leu Val Arg Ser Met Val Thr Ala
340 345 350
<210> 24
<211> 351
<212> PRT
<213> 人工序列(Synthetic sequences)
<400> 24
Val Gly Cys Ser Val Asp Phe Ser Lys Lys Glu Thr Arg Cys Gly Thr
1 5 10 15
Gly Val Phe Val Tyr Asn Asp Val Glu Ala Trp Arg Asp Arg Tyr Lys
20 25 30
Tyr His Pro Asp Ser Pro Arg Arg Leu Ala Ala Ala Val Lys Gln Ala
35 40 45
Trp Glu Asp Gly Ile Cys Gly Ile Ser Ser Val Ser Arg Met Glu Asn
50 55 60
Ile Met Trp Arg Ser Val Glu Gly Glu Leu Asn Ala Ile Leu Glu Glu
65 70 75 80
Asn Gly Val Gln Leu Thr Val Val Val Gly Ser Val Lys Asn Pro Met
85 90 95
Trp Arg Gly Pro Gln Arg Leu Pro Val Pro Val Asn Glu Leu Pro His
100 105 110
Gly Trp Lys Ala Trp Gly Lys Ser Tyr Phe Val Arg Ala Ala Lys Thr
115 120 125
Asn Asn Ser Phe Val Val Asp Gly Asp Thr Leu Lys Glu Cys Pro Leu
130 135 140
Lys His Arg Ala Trp Asn Ser Phe Leu Val Glu Asp His Gly Phe Gly
145 150 155 160
Val Phe His Thr Ser Val Trp Leu Lys Val Arg Glu Asp Tyr Ser Leu
165 170 175
Glu Cys Asp Pro Ala Val Ile Gly Thr Ala Val Lys Gly Lys Glu Ala
180 185 190
Val His Ser Asp Leu Gly Tyr Trp Ile Glu Ser Glu Lys Asn Asp Thr
195 200 205
Trp Arg Leu Lys Arg Ala His Leu Ile Glu Met Lys Thr Cys Glu Trp
210 215 220
Pro Lys Ser His Thr Leu Trp Thr Asp Gly Ile Glu Glu Ser Asp Leu
225 230 235 240
Ile Ile Pro Lys Ser Leu Ala Gly Pro Leu Ser His His Asn Thr Arg
245 250 255
Glu Gly Tyr Arg Thr Gln Met Lys Gly Pro Trp His Ser Glu Glu Leu
260 265 270
Glu Ile Arg Phe Glu Glu Cys Pro Gly Thr Lys Val His Val Glu Glu
275 280 285
Thr Cys Gly Thr Arg Gly Pro Ser Leu Arg Ser Thr Thr Ala Ser Gly
290 295 300
Arg Val Ile Glu Glu Trp Cys Cys Arg Glu Cys Thr Met Pro Pro Leu
305 310 315 320
Ser Phe Arg Ala Lys Asp Gly Cys Trp Tyr Gly Met Glu Ile Arg Pro
325 330 335
Arg Lys Glu Pro Glu Ser Asn Leu Val Arg Ser Met Val Thr Ala
340 345 350
<210> 25
<211> 351
<212> PRT
<213> 人工序列(Synthetic sequences)
<400> 25
Ser Gly Cys Val Ile Asn Trp Lys Gly Arg Glu Leu Lys Cys Gly Ser
1 5 10 15
Gly Ile Phe Val Thr Asn Glu Val His Thr Trp Thr Glu Gln Tyr Lys
20 25 30
Phe Gln Ala Asp Ser Pro Lys Arg Leu Ser Ala Ala Ile Gly Lys Ala
35 40 45
Trp Glu Glu Gly Val Cys Gly Ile Arg Ser Ala Thr Arg Leu Glu Asn
50 55 60
Ile Met Trp Lys Gln Ile Ser Asn Glu Leu Asn His Ile Leu Leu Glu
65 70 75 80
Asn Asp Met Lys Leu Thr Val Val Val Gly Asp Val Thr Gly Ile Leu
85 90 95
Ala Gln Gly Lys Lys Met Ile Arg Pro Gln Pro Met Glu His Lys Tyr
100 105 110
Ser Trp Lys Ser Trp Gly Lys Ala Lys Ile Thr Gly Ala Asp Val Gln
115 120 125
Asn Thr Thr Phe Ile Ile Asp Gly Pro Asn Thr Pro Glu Cys Pro Asp
130 135 140
Asn Gln Arg Ala Trp Asn Ile Trp Glu Val Glu Asp Tyr Gly Phe Gly
145 150 155 160
Val Phe Thr Thr Asn Ile Trp Leu Lys Leu Arg Asp Ser Tyr Thr Gln
165 170 175
Val Cys Asp His Arg Leu Met Ser Ala Ala Ile Lys Asp Ser Lys Ala
180 185 190
Val His Ala Asp Met Gly Tyr Trp Ile Glu Ser Glu Lys Asn Glu Thr
195 200 205
Trp Lys Leu Glu Arg Ala Ser Phe Ile Glu Val Lys Thr Cys Ile Trp
210 215 220
Pro Arg Ser His Thr Leu Trp Ser Asn Gly Val Leu Glu Ser Glu Met
225 230 235 240
Ile Ile Pro Lys Ile Tyr Gly Gly Pro Val Ser Gln His Asn Tyr Arg
245 250 255
Pro Gly Tyr Phe Thr Gln Thr Ala Gly Pro Trp His Leu Gly Lys Leu
260 265 270
Glu Leu Asp Phe Asp Leu Cys Glu Gly Thr Thr Val Val Val Asp Glu
275 280 285
Asn Cys Gly Asn Arg Gly Pro Ser Leu Arg Thr Thr Thr Val Thr Gly
290 295 300
Lys Thr Ile His Glu Trp Cys Cys Arg Ser Cys Thr Leu Pro Pro Leu
305 310 315 320
Arg Phe Lys Gly Glu Asp Gly Cys Trp Tyr Gly Met Glu Ile Arg Pro
325 330 335
Val Lys Glu Lys Glu Glu Asn Leu Val Lys Ser Met Val Ser Ala
340 345 350
<210> 26
<211> 351
<212> PRT
<213> 人工序列(Synthetic sequences)
<400> 26
Ser Gly Cys Val Val Ser Trp Lys Asn Lys Glu Leu Lys Cys Gly Ser
1 5 10 15
Gly Ile Phe Ile Thr Asp Asn Val His Thr Trp Thr Glu Gln Tyr Lys
20 25 30
Phe Gln Pro Glu Ser Pro Ser Lys Leu Ala Ser Ala Ile Gln Lys Ala
35 40 45
His Glu Glu Gly Ile Cys Gly Ile Arg Ser Val Thr Arg Leu Glu Asn
50 55 60
Leu Met Trp Lys Gln Ile Thr Pro Glu Leu Asn His Ile Leu Ser Glu
65 70 75 80
Asn Glu Val Lys Leu Thr Ile Met Thr Gly Asp Ile Lys Gly Ile Met
85 90 95
Gln Ala Gly Lys Arg Ser Leu Arg Pro Gln Pro Thr Glu Leu Lys Tyr
100 105 110
Ser Trp Lys Thr Trp Gly Lys Ala Lys Met Leu Ser Thr Glu Ser His
115 120 125
Asn Gln Thr Phe Leu Ile Asp Gly Pro Glu Thr Ala Glu Cys Pro Asn
130 135 140
Thr Asn Arg Ala Trp Asn Ser Leu Glu Val Glu Asp Tyr Gly Phe Gly
145 150 155 160
Val Phe Thr Thr Asn Ile Trp Leu Lys Leu Lys Glu Lys Gln Asp Val
165 170 175
Phe Cys Asp Ser Lys Leu Met Ser Ala Ala Ile Lys Asp Asn Arg Ala
180 185 190
Val His Ala Asp Met Gly Tyr Trp Ile Glu Ser Ala Leu Asn Asp Thr
195 200 205
Trp Lys Ile Glu Lys Ala Ser Phe Ile Glu Val Lys Asn Cys His Trp
210 215 220
Pro Lys Ser His Thr Leu Trp Ser Asn Gly Val Leu Glu Ser Glu Met
225 230 235 240
Ile Ile Pro Lys Asn Leu Ala Gly Pro Val Ser Gln His Asn Tyr Arg
245 250 255
Pro Gly Tyr His Thr Gln Ile Thr Gly Pro Trp His Leu Gly Lys Leu
260 265 270
Glu Met Asp Phe Asp Phe Cys Asp Gly Thr Thr Val Val Val Thr Glu
275 280 285
Asp Cys Gly Asn Arg Gly Pro Ser Leu Arg Thr Thr Thr Ala Ser Gly
290 295 300
Lys Leu Ile Thr Glu Trp Cys Cys Arg Ser Cys Thr Leu Pro Pro Leu
305 310 315 320
Arg Tyr Arg Gly Glu Asp Gly Cys Trp Tyr Gly Met Glu Ile Arg Pro
325 330 335
Leu Lys Glu Lys Glu Glu Asn Leu Val Asn Ser Leu Val Thr Ala
340 345 350
<210> 27
<211> 351
<212> PRT
<213> 人工序列(Synthetic sequences)
<400> 27
Met Gly Cys Val Ile Asn Trp Lys Gly Lys Glu Leu Lys Cys Gly Asn
1 5 10 15
Gly Ile Phe Val Thr Asn Glu Val His Thr Trp Thr Glu Gln Tyr Lys
20 25 30
Phe Gln Ala Asp Ser Pro Lys Arg Leu Ala Thr Ala Ile Ala Gly Ala
35 40 45
Trp Glu Asn Gly Val Cys Gly Ile Arg Ser Thr Thr Arg Met Glu Asn
50 55 60
Leu Leu Trp Lys Gln Ile Ala Asn Glu Leu Asn Tyr Ile Leu Trp Glu
65 70 75 80
Asn Asn Ile Lys Leu Thr Val Val Val Gly Asp Ile Thr Gly Val Leu
85 90 95
Glu Gln Gly Lys Arg Thr Leu Thr Pro Gln Pro Met Glu Leu Lys Tyr
100 105 110
Ser Trp Lys Thr Trp Gly Lys Ala Lys Ile Val Thr Ala Glu Thr Gln
115 120 125
Asn Ser Ser Phe Ile Ile Asp Gly Pro Asn Thr Pro Glu Cys Pro Ser
130 135 140
Ala Ser Arg Ala Trp Asn Val Trp Glu Val Glu Asp Tyr Gly Phe Gly
145 150 155 160
Val Phe Thr Thr Asn Ile Trp Leu Lys Leu Arg Glu Met Tyr Thr Gln
165 170 175
Leu Cys Asp His Arg Leu Met Ser Ala Ala Val Lys Asp Glu Arg Ala
180 185 190
Val His Ala Asp Met Gly Tyr Trp Ile Glu Ser Gln Lys Asn Gly Ser
195 200 205
Trp Lys Leu Glu Lys Ala Ser Leu Ile Glu Val Lys Thr Cys Thr Trp
210 215 220
Pro Lys Ser His Thr Leu Trp Ser Asn Gly Val Leu Glu Ser Asp Met
225 230 235 240
Ile Ile Pro Lys Ser Leu Ala Gly Pro Ile Ser Gln His Asn Tyr Arg
245 250 255
Pro Gly Tyr His Thr Gln Thr Ala Gly Pro Trp His Leu Gly Lys Leu
260 265 270
Glu Leu Asp Phe Asn Tyr Cys Glu Gly Thr Thr Val Val Ile Thr Glu
275 280 285
Asn Cys Gly Thr Arg Gly Pro Ser Leu Arg Thr Thr Thr Val Ser Gly
290 295 300
Lys Leu Ile His Glu Trp Cys Cys Arg Ser Cys Thr Leu Pro Pro Leu
305 310 315 320
Arg Tyr Met Gly Glu Asp Gly Cys Trp Tyr Gly Met Glu Ile Arg Pro
325 330 335
Ile Asn Glu Lys Glu Glu Asn Met Val Lys Ser Leu Val Ser Ala
340 345 350
<210> 28
<211> 351
<212> PRT
<213> 人工序列(Synthetic sequences)
<400> 28
Met Gly Cys Val Val Ser Trp Asn Gly Lys Glu Leu Lys Cys Gly Ser
1 5 10 15
Gly Ile Phe Val Ile Asp Asn Val His Thr Arg Thr Glu Gln Tyr Lys
20 25 30
Phe Gln Pro Glu Ser Pro Ala Arg Leu Ala Ser Ala Ile Leu Asn Ala
35 40 45
His Lys Asp Gly Val Cys Gly Val Arg Ser Thr Thr Arg Leu Glu Asn
50 55 60
Val Met Trp Lys Gln Ile Thr Asn Glu Leu Asn Tyr Val Leu Trp Glu
65 70 75 80
Gly Gly His Asp Leu Thr Val Val Ala Gly Asp Val Lys Gly Val Leu
85 90 95
Thr Glu Gly Lys Arg Ala Leu Thr Pro Pro Val Asn Asp Leu Lys Tyr
100 105 110
Ser Trp Lys Thr Trp Gly Lys Ala Lys Ile Phe Thr Leu Glu Ala Arg
115 120 125
Asn Ser Thr Phe Leu Ile Asp Gly Pro Asp Thr Ser Glu Cys Pro Asn
130 135 140
Glu Arg Arg Ala Trp Asn Phe Leu Glu Val Glu Asp Tyr Gly Phe Gly
145 150 155 160
Met Phe Thr Thr Asn Ile Trp Met Lys Phe Arg Glu Gly Ser Ser Glu
165 170 175
Val Cys Asp His Arg Leu Met Ser Ala Ala Ile Lys Asp Gln Lys Ala
180 185 190
Val His Ala Asp Met Gly Tyr Trp Ile Glu Ser Ser Lys Asn Gln Thr
195 200 205
Trp Gln Ile Glu Lys Ala Ser Leu Ile Glu Val Lys Thr Cys Leu Trp
210 215 220
Pro Lys Thr His Thr Leu Trp Ser Asn Gly Val Leu Glu Ser Gln Met
225 230 235 240
Leu Ile Pro Arg Ser Tyr Ala Gly Pro Phe Ser Gln His Asn Tyr Arg
245 250 255
Gln Gly Tyr Ala Thr Gln Thr Met Gly Pro Trp His Leu Gly Lys Leu
260 265 270
Glu Ile Asn Phe Gly Glu Cys Pro Gly Thr Thr Val Ala Ile Gln Glu
275 280 285
Asp Cys Gly His Arg Gly Pro Ser Leu Arg Thr Thr Thr Ala Ser Gly
290 295 300
Lys Leu Val Thr Gln Trp Cys Cys Arg Ser Cys Ala Met Pro Pro Leu
305 310 315 320
Arg Phe Leu Gly Glu Asp Gly Cys Trp Tyr Gly Met Glu Ile Arg Pro
325 330 335
Leu Ser Glu Lys Glu Glu Asn Met Val Lys Ser Gln Val Thr Ala
340 345 350
<210> 29
<211> 351
<212> PRT
<213> 人工序列(Synthetic sequences)
<400> 29
Thr Gly Cys Ala Ile Asp Ile Ser Arg Gln Glu Leu Arg Cys Gly Ser
1 5 10 15
Gly Val Phe Ile His Asn Asp Val Glu Ala Trp Met Asp Arg Tyr Lys
20 25 30
Tyr Tyr Pro Glu Thr Pro Gln Gly Leu Ala Lys Ile Ile Gln Lys Ala
35 40 45
His Lys Glu Gly Val Cys Gly Leu Arg Ser Val Ser Arg Leu Glu His
50 55 60
Gln Met Trp Glu Ala Val Lys Asp Glu Leu Asn Thr Leu Leu Lys Glu
65 70 75 80
Asn Gly Val Asp Leu Ser Val Val Val Glu Lys Gln Glu Gly Met Tyr
85 90 95
Lys Ser Ala Pro Lys Arg Leu Thr Ala Thr Thr Glu Lys Leu Glu Ile
100 105 110
Gly Trp Lys Ala Trp Gly Lys Ser Ile Leu Phe Ala Pro Glu Leu Ala
115 120 125
Asn Asn Thr Phe Val Val Asp Gly Pro Glu Thr Lys Glu Cys Pro Thr
130 135 140
Gln Asn Arg Ala Trp Asn Ser Leu Glu Val Glu Asp Phe Gly Phe Gly
145 150 155 160
Leu Thr Ser Thr Arg Met Phe Leu Lys Val Arg Glu Ser Asn Thr Thr
165 170 175
Glu Cys Asp Ser Lys Ile Ile Gly Thr Ala Val Lys Asn Asn Leu Ala
180 185 190
Ile His Ser Asp Leu Ser Tyr Trp Ile Glu Ser Arg Leu Asn Asp Thr
195 200 205
Trp Lys Leu Glu Arg Ala Val Leu Gly Glu Val Lys Ser Cys Thr Trp
210 215 220
Pro Glu Thr His Thr Leu Trp Gly Asp Gly Ile Leu Glu Ser Asp Leu
225 230 235 240
Ile Ile Pro Val Thr Leu Ala Gly Pro Arg Ser Asn His Asn Arg Arg
245 250 255
Pro Gly Tyr Lys Thr Gln Asn Gln Gly Pro Trp Asp Glu Gly Arg Val
260 265 270
Glu Ile Asp Phe Asp Tyr Cys Pro Gly Thr Thr Val Thr Leu Ser Glu
275 280 285
Ser Cys Gly His Arg Gly Pro Ala Thr Arg Thr Thr Thr Glu Ser Gly
290 295 300
Lys Leu Ile Thr Asp Trp Cys Cys Arg Ser Cys Thr Leu Pro Pro Leu
305 310 315 320
Arg Tyr Gln Thr Asp Ser Gly Cys Trp Tyr Gly Met Glu Ile Arg Pro
325 330 335
Gln Arg His Asp Glu Lys Thr Leu Val Gln Ser Gln Val Asn Ala
340 345 350

Claims (10)

1.一种黄病毒抗体，其特征在于，所述抗体包含如下(1)-(4)中任一氨基酸序列：
(1)如氨基酸序列SEQ ID NO：1所示的抗体重链可变区，如氨基酸序列SEQ ID NO：2所示的抗体轻链可变区；
(2)如氨基酸序列SEQ ID NO：3所示的抗体重链可变区，如氨基酸序列SEQ ID NO：4所示的抗体轻链可变区；
(3)如氨基酸序列SEQ ID NO：5所示的抗体重链可变区，如氨基酸序列SEQ ID NO：6所示的抗体轻链可变区；
(4)如氨基酸序列SEQ ID NO：7所示的抗体重链可变区，如氨基酸序列SEQ ID NO：8所示的抗体轻链可变区。
2.如权利要求1所述的抗体，其特征在于，包含所述氨基酸序列SEQ ID NO：9所示的抗体重链恒定区，如氨基酸序列SEQ ID NO：10所示的抗体轻链恒定区。
3.如权利要求1所述的抗体，其特征在于，所述氨基酸轻链均为K型轻链。
4.一种核酸分子，其中，所述核酸分子包含编码以上所述抗体的核苷酸序列。
5.包含权利要求4中所述核酸分子的表达载体。
6.包含权利要求5中所述表达载体的宿主细胞。
7.一种药物组合物，其特征在于，包含权利要求1至3中任一所述的抗体。
8.一种检测试剂，其特征在于，包含权利要求1至3中任一所述的抗体。
9.一种检测试剂盒，其特征在于，包含权利要求1至3中任一所述的抗体。
10.权利要求1至3中任一所述抗体在制备检测、治疗和/或预防黄病毒药物或试剂上的应用。
CN202110955389.5A 2021-08-19 2021-08-19 黄病毒抗体及其应用 Active CN113683691B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110955389.5A CN113683691B (zh) 2021-08-19 2021-08-19 黄病毒抗体及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110955389.5A CN113683691B (zh) 2021-08-19 2021-08-19 黄病毒抗体及其应用

Publications (2)

Publication Number Publication Date
CN113683691A true CN113683691A (zh) 2021-11-23
CN113683691B CN113683691B (zh) 2023-05-23

Family

ID=78580751

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110955389.5A Active CN113683691B (zh) 2021-08-19 2021-08-19 黄病毒抗体及其应用

Country Status (1)

Country Link
CN (1) CN113683691B (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111320688A (zh) * 2018-12-17 2020-06-23 中国科学院天津工业生物技术研究所 一种黄病毒中和抗体、其制备方法及应用
US20200363415A1 (en) * 2016-02-11 2020-11-19 Massachusetts Institute Of Technology Anti-Dengue Virus NS1 Protein Monoclonal Antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200363415A1 (en) * 2016-02-11 2020-11-19 Massachusetts Institute Of Technology Anti-Dengue Virus NS1 Protein Monoclonal Antibodies
CN111320688A (zh) * 2018-12-17 2020-06-23 中国科学院天津工业生物技术研究所 一种黄病毒中和抗体、其制备方法及应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ZHAO GAO: "Development of antibody-based assays for high throughput discovery and mechanistic study of antiviral agents against yellow fever virus", 《ANTIVIRAL RESEARCH》 *
刘朵朵: "黄热病毒非结构蛋白1(YFV-NS1)在病毒感染早期的诊断价值及抗YFV-NS1单克隆抗体的制备", 《万方学术》 *

Also Published As

Publication number Publication date
CN113683691B (zh) 2023-05-23

Similar Documents

Publication Publication Date Title
CN111592594B (zh) 一种抗新型冠状病毒的单克隆抗体及其应用
CN110172095A (zh) 一种高中和活性的寨卡病毒人源单克隆抗体及其应用
CN106589116B (zh) 一种黄病毒人源单克隆抗体及应用
CN113929774A (zh) 一种新型冠状病毒及其突变体的单克隆抗体及其应用
WO2023130770A1 (zh) 一种全人源抗新冠病毒广谱中和抗体zw2g10及应用
CN107531779A (zh) 血清型交叉反应性登革热中和抗体和其用途
CN110343174B (zh) 一种高亲和力的黄热病毒人源单克隆抗体及其应用
CN112076316B (zh) 一种双抗体组合物及在制备covid-19治疗药物中的应用
CN113683691B (zh) 黄病毒抗体及其应用
CN114989291B (zh) 一种靶向RBD的抗SARS-CoV-2全人源化单克隆抗体及应用
CN113621058B (zh) 黄热病毒抗体及其应用
CN115433285A (zh) 靶向冠状病毒的抗体及其应用
CN113683690B (zh) 针对黄热病毒ns1蛋白的抗体及其应用
CN110922478B (zh) 针对特异表位的抗基孔肯雅热的全人源单克隆抗体及应用
CN110343173B (zh) 一种高功能活性的黄热病毒人源单克隆抗体及其应用
CN111138527B (zh) 抗埃博拉病毒糖蛋白gp1亚基的单克隆抗体4f1及应用
CN110343172B (zh) 一种高灵敏度的黄热病毒人源单克隆抗体及其应用
CN113817031B (zh) 一种分离的抗原表位多肽
CN110590956B (zh) 由两个炭疽非保护性抗体组成的新型双特异保护性抗体
CN111138529B (zh) 具有独特结合位点的抗ebov的gp2亚基的单克隆抗体5e1
CN108728463A (zh) 一种表达IgG抗体的微环DNA载体及其制备方法和应用
CN108299559B (zh) Zaire型埃博拉病毒检测抗体及其制备方法及应用
WO2020093672A1 (zh) 一种广谱中和多种埃博拉病毒的单克隆抗体 2g1 及应用
CN114989292A (zh) 一种抗SARS-CoV-2全人源化单克隆抗体及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant